Study summary · research use only
Perspectives in weight control in diabetes - Survodutide
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review/perspective (human patients discussed; Phase II trial data referenced but not detailed) discusses survodutide, a 29-amino acid, glucagon-derived dual agonist of the glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R), developed to mimic the natural gut hormone oxyntomodulin for type 2 diabetes mellitus and obesity. The authors describe survodutide as containing a C18 diacid that binds albumin, prolonging its half-life to allow once-weekly subcutaneous dosing, with GCGR agonism intended to add energy-expenditure effects to the appetite-reducing action of GLP-1R agonism. The piece references a Phase II trial in patients with type 2 diabetes mellitus and obesity in which survodutide was associated with glucose-lowering changes and clinically meaningful body weight loss, describing dual GCGR/GLP-1R agonism as an approach for reducing glycated haemoglobin and body weight in this population.
Abstract
Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved treatments for Type 2 diabetes mellitus, with liraglutide and semaglutide also approved for the treatment of obesity. The natural gut hormone oxyntomodulin is a weak dual agonist of the glucagon receptor (GCGR) and GLP-1R. Development of poly-agonists mimicking oxyntomodulin, such as the novel dual GCGR/GLP-1R agonist survodutide, represents an important step towards a more effective treatment for people with Type 2 diabetes mellitus and obesity. Survodutide is a 29-amino acid peptide derived from glucagon, with the incorporation of potent GLP-1 activities. It contains a C18 diacid which mediates binding to albumin, thereby prolonging the half-life to enable once-weekly subcutaneous dosing. The utilisation of GCGR agonism aims to enhance body weight-lowering effects by increasing energy expenditure in addition to the anorectic action of GLP-1R agonists. Glucose-lowering efficacy of survodutide has been demonstrated in a Phase II trial in patients with Type 2 diabetes mellitus and obesity and was associated with clinically meaningful body weight loss. These data highlight the potential of dual GCGR/GLP-1R agonism for reducing glycated haemoglobin and body weight in patients with Type 2 diabetes mellitus, and for greater therapeutic efficacy compared with GLP-1R agonism alone.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.